On June 27, 2017, Pfizer broke ground on a state-of-the art Research and Development (R&D) and process development facility in Chesterfield, Missouri. The site will be owned by Pfizer, building on our 15-year history in Missouri. The sprawling 295,000 square foot facility will be home to Pfizer’s BioTherapeutics Pharmaceutical Sciences group and enabling partners.
This site will bring together more than 450 employees who are currently working at different locations in the St. Louis area. Pfizer expects to hire an additional 80 employees over the coming years to support research at the site.
"We've been proud to call Missouri home since 2002," said John Ludwig, Senior Vice President of BioTherapeutics Pharmaceutical Sciences for Pfizer. "During this time, we’ve benefitted from the excellent life sciences workforce based in Missouri, and also from a strong partnership with the State, St. Louis County, and the St. Louis Economic Development Partnership. All of these were important factors as we sought a new home where we could continue to evolve our business over the coming years."
The BioTherapeutics Pharmaceutical Sciences group is responsible for advancing Pfizer’s biologics, vaccines, and gene therapy portfolio by developing manufacturing processes and dosage forms applying state-of-the-art analytical technologies, conducting non-GMP manufacturing and scale-up studies, and conducting GMP clinical and commercial cell banking operations.
This critical work enables the development of potential new medicines to treat ailments in oncology, rare disease, internal medicine, inflammation & immunology, and vaccines, including biosimilars. The St. Louis site is an important part of Pfizer’s worldwide R&D network, which includes locations in La Jolla, Calif.; Pearl River, NY; Groton, Conn.; and Cambridge and Andover, Mass.
Construction at this site is expected to be complete by mid-2019.